Evidence map›Paper›PMID 41531254›Full record

ArticleCardiovascular research2026

Dual roles of ADAM17: from fibroblast foe to myofibroblast friend.

Prabhat Ranjan, Suresh Kumar Verma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Prabhat RanjanDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Suresh Kumar VermaDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-0739-1302

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
IL10 REGULATION OF FIBROBLAST PROGENITOR CELL MEDIATED CARDIAC FIBROSISR01HL135060 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VERMA, SURESH K · 2017 to 2021
$1.9M
RNA methylation in the progress of heart failureR01HL173677 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Suresh K Verma · 2025 to 2026
$1.1M
AHA-Career Development 23CDA1047979American Heart Association 958292American Heart Association-American Stroke Association 958292NHLBI NIH HHS R01 HL135060NHLBI NIH HHS R01 HL173677NIDDK NIH HHS P30 DK079626NIH HHS 5P30DK079626NIH HHS HL135060NIH HHS HL173677UAB Diabetic Research Center
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41531254
PMCPMC13370435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.